Personal
Become a Client
Viking Therapeutics Inc (USD)
VKTX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range5.60 | 6.01
52-Wk Range- | -
Last Close5.75
Mkt Cap (m)449.08
Dividend yield-
ISINUS92686J1060
Volume629,025.00
Exchange VenueNAS

Company Profile

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Key Information
Price/Earning-
Price/Book1.89
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-15.15
Debt/Equity0.00

Documents

Prospectus
en 02/08/2019
Annual Report
en 31/12/2020

Please refer to the below issuer website for further documents.

http://www.vikingtherapeutics.com

Financials

Income Statement
USD201520162017201820192020
Revenue (m)0.000.000.000.000.000.00
Operating Income (m)-12.00-13.85-19.07-26.16-32.69-42.66
Net Income (m)-23.40-14.73-20.58-22.06-25.78-39.50
Basic EPS-3.68-0.90-0.79-0.38-0.36-0.54
Avg. Diluted Shares Outstanding (m)6.3616.2825.9857.5871.9672.60
Balance Sheet
USD201520162017201820192020
Current Assets (m)15.2013.9721.85302.13283.50256.10
Non Current Assets (m)0.240.560.270.180.760.40
Total Assets (m)15.4414.5422.12302.31284.26256.50
Current Liabilities (m)1.986.488.664.556.7812.13
Total Liabilities (m)------
Total Equity (m)8.728.0413.46297.75277.12244.34
Cash Flows
USD201520162017201820192020
Operating Cash Flows (m)-8.73-11.07-14.76-18.76-24.75-21.78
Capital Expenditure (m)------
Figures are quoted in USD unless stated otherwise
0.26 (4.52%)
$
6.01
Last Price